A federal judge in Camden, N.J., has remanded to state court 15 suits over birth defects in children born to mothers who took Forest Laboratories’ antidepressants Celexa and Lexapro for lack of subject matter jurisdiction.
U.S. District Judge Robert Kugler rejected the defendants’ assertion that federal jurisdiction is proper because the cases require the court to address questions about the Food and Drug Administration’s labeling of the drugs. Kugler also rejected the defendants’ claims that defendant Forest Research Institute of Jersey City was fraudulently joined as a defendant.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]